1
|
Obi N, Jung AY, Maurer T, Huebner M, Johnson T, Behrens S, Jaskulski S, Becher H, Chang-Claude J. Association of circulating leptin, adiponectin, and resistin concentrations with long-term breast cancer prognosis in a German patient cohort. Sci Rep 2021; 11:23526. [PMID: 34876619 PMCID: PMC8651788 DOI: 10.1038/s41598-021-02958-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Accepted: 11/19/2021] [Indexed: 12/23/2022] Open
Abstract
Adipokines including leptin, adiponectin and resistin have been linked to risk of obesity-related cancers potentially through low-grade chronic inflammation pathways. We aimed to assess the role of post-diagnosis circulating adipokines on long-term prognosis in a prospective breast cancer cohort. Adipokines were measured in blood collected at baseline shortly after diagnosis (2002-2005) and at follow-up (2009) from 3112 breast cancer patients enrolled in the population-based MARIE study. Half of the patients had measurements at both time-points. All-cause mortality, breast cancer specific mortality and recurrences were ascertained up to June 2015 (11 years median follow-up). Associations with time-varying adipokine concentrations overall and stratified by estrogen and progesterone receptor (ERPR) were evaluated using adjusted proportional hazard regression. At baseline (n = 2700) and follow-up (n = 2027), median concentrations for leptin, adiponectin and resistin were 4.6 and 2.7 ng/ml, 24.4 and 30.0 mg/l, 15.4 and 26.2 ng/ml, respectively. After adjustment, there was no evidence for associations between adipokines and any outcome overall. In ERPR negative tumors, highest vs. lowest quintile of adiponectin was significantly associated with increased breast cancer specific mortality (HR 2.51, 95%CI 1.07-5.92). Overall, post-diagnosis adipokines were not associated with long-term outcomes after breast cancer. In patients with ERPR negative tumors, higher concentrations of adiponectin may be associated with increased breast cancer specific mortality and warrant further investigation.
Collapse
Affiliation(s)
- Nadia Obi
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
| | - Audrey Y Jung
- Division of Cancer Epidemiology/Unit of Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany
| | - Tabea Maurer
- Cancer Epidemiology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Marianne Huebner
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
- Department of Statistics and Probability, Michigan State University, East Lansing, MI, 48824, USA
| | - Theron Johnson
- Division of Cancer Epidemiology/Unit of Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany
| | - Sabine Behrens
- Division of Cancer Epidemiology/Unit of Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany
| | - Stefanie Jaskulski
- Division of Cancer Epidemiology/Unit of Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany
- Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical Center, University Medical Center, University of Freiburg, Freiburg, Germany
| | - Heiko Becher
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology/Unit of Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany
- Cancer Epidemiology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
2
|
Abstract
BACKGROUND Accumulating data have found that adiponectin is involved in development of breast cancer (BC). However, these results were inconsistent. METHOD A systematic search in PubMed, Embase, ISI Web of Science, and Chinese National Knowledge Infrastructure databases were conducted up to October 1, 2017. The standardized mean difference (SMD) with 95% confidence interval was applied to pool the effect size. RESULTS Finally, 31 eligible studies were included in this meta-analysis. The overall results indicated that serum adiponectin levels in BC cases were significantly lower than the controls (SMD = -0.33, P < 0.0001). As for the subgroup analysis of menstrual status, serum adiponectin levels were significantly lower in pre- and postmenopausal BC cases. Moreover, the subgroup analysis by ethnicity in pre- and postmenopausal group indicated an inverse association between adiponectin levels and BC risk in Asian population, but not in Caucasian population. CONCLUSION The present meta-analysis suggests that low serum adiponectin concentration may be associated with an increased BC risk in premenopausal and postmenopausal women, especially among Asians. Adiponectin may serve as a biomarker of BC risk and help to identify subjects at high risk for BC development.
Collapse
Affiliation(s)
- Li Gu
- Department of Obstetrics, West China Women's and Children's Hospital
- Key Laboratory of Birth and Related Diseases of Women and Children, Sichuan University
| | - Chang Cao
- Department of Cosmetic Plastic and Burns surgery, West China Hospital, Sichuan University, Chengdu
| | - Jing Fu
- International Education School, Southwest Medical University, Luzhou
| | - Qian Li
- Department of Operations Management, West China Hospital, Sichuan University
| | - De-Hua Li
- Key Laboratory of Birth and Related Diseases of Women and Children, Sichuan University
- Department of West China Second University Hospital Quality improvement, West China Women's and Children's Hospital, Chengdu
| | - Ming-Yao Chen
- Dazhou vocational and technical college, Dazhou, PR China
| |
Collapse
|
3
|
Ye J, Liang Z, Liang Q, Zhang J, Mao S, Liang R. Adiponectin is associated with poor prognosis in carcinoma patients: evidence from a meta-analysis. Lipids Health Dis 2015; 14:154. [PMID: 26612049 PMCID: PMC4661958 DOI: 10.1186/s12944-015-0157-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Accepted: 11/24/2015] [Indexed: 01/16/2023] Open
Abstract
Background Studies have come to conflicting conclusions about whether adiponectin (APN) expression is associated with cancer prognosis. To help resolve this question, we meta-analyzed the available evidence. Methods PubMed, EMBASE, the Cochrane Library, the Chinese Biological Medical Database and the Chinese National Knowledge Infrastructure Database were systematically searched to identify all eligible studies examining APN expression and prognosis for patients with any type of cancer. Pooled hazard ratios (HRs) and corresponding 95 % confidence intervals (CIs) related to overall survival (OS) or disease-free survival (DFS) were calculated. Results Ten studies involving 999 patients were meta-analyzed. Analysis across all patients revealed no significant association between high/positive APN expression and DFS, but they did show a significant association between high/positive APN expression and OS (HR 1.51, 95 %CI 1.21 to 1.89). Subgroup analysis showed that high/positive APN expression in non-Asians was significantly associated with both DFS (HR 1.36, 95 % CI 1.03 to 1.80) and OS (HR 1.53, 95 %CI 1.20 to 1.96), but no such associations were observed in Asians. In addition, high/positive APN expression was significantly associated with OS across all patients with hepatocellular carcinoma (HR 1.89, 95 %CI 1.20 to 2.98). Conclusions The available evidence suggests that high/positive APN expression is associated with poor prognosis for patients with various carcinomas, especially for non-Asian cancer patients and for all patients with hepatocellular carcinoma. These findings should be confirmed and extended in large, well-designed studies.
Collapse
Affiliation(s)
- Jiaxiang Ye
- Department of Medical Oncology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, No. 71, Hedi Road, Nanning, Guangxi, 530021, P.R. China.
| | - Zhongguo Liang
- Department of Medical Oncology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, No. 71, Hedi Road, Nanning, Guangxi, 530021, P.R. China
| | - Qian Liang
- Graduate School of Guangxi Medical University, Nanning, Guangxi, 530021, P.R. China
| | - Jinyan Zhang
- Department of Medical Oncology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, No. 71, Hedi Road, Nanning, Guangxi, 530021, P.R. China
| | - Sufei Mao
- Department of Medical Oncology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, No. 71, Hedi Road, Nanning, Guangxi, 530021, P.R. China
| | - Rui Liang
- Department of Anesthesiology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, No. 71, Hedi Road, Nanning, Guangxi, 530021, P.R. China.
| |
Collapse
|